Results 141 to 150 of about 13,547 (178)
Some of the next articles are maybe not open access.
Collection of Czechoslovak Chemical Communications, 1995
Twenty amino acid residues peptides derived from the N-terminal domain of glycoprotein gp41 exhibit four different types of reactivity with human sera in the course of seroconversion. The differences in the accessibility of the peptide by immune apparatus can result from different binding of the knobs formed by trimers of glycoprotein gp120 to the ...
Dalibor Štys +5 more
openaire +1 more source
Twenty amino acid residues peptides derived from the N-terminal domain of glycoprotein gp41 exhibit four different types of reactivity with human sera in the course of seroconversion. The differences in the accessibility of the peptide by immune apparatus can result from different binding of the knobs formed by trimers of glycoprotein gp120 to the ...
Dalibor Štys +5 more
openaire +1 more source
Thermodynamics of Peptide Inhibitor Binding to HIV-1 gp41
Biochemistry, 2001The gp41 subunit of the human immunodeficiency virus type 1 envelope glycoprotein mediates fusion of the cellular and viral membranes. The gp41 ectodomain is a trimer of alpha-helical hairpins, where N-terminal helices form a parallel three-stranded coiled-coil core and C-terminal helices pack around the core.
J L, Cole, V M, Garsky
openaire +2 more sources
Thermostability of the HIV gp41 Wild-Type and Loop Mutations
Protein & Peptide Letters, 2006The HIV and SIV gp41 ectodomains are extremely stable to chemical and thermal denaturation and the observed stability has been proposed to be an important thermodynamic driving force for gp41-mediated fusion of the viral and target cell membranes. The importance of the disulphide bond and surrounding residues within the HIV gp41 loop have been assayed ...
Amy, Jacobs +2 more
openaire +2 more sources
HIV-1 gp41 as a Target for Viral Entry Inhibition
Current Pharmaceutical Design, 2004The recent success of the fusion inhibitor T-20 (enfuvirtide) in clinical studies has ushered in a new chapter in the development of anti-HIV-1 therapeutics. T-20 is the first FDA-approved drug that targets the viral transmembrane protein gp41. This protein, along with gp120, promotes viral entry through a coordinated cascade of conformational ...
Michael J, Root, H Kirby, Steger
openaire +2 more sources
Cloning, expression and nanodiscs assemble of recombinant HIV-1 gp41
Microbial Pathogenesis, 2020Mostafa A Elbahnasawy
exaly
Three-dimensional solution structure of the 44kDa ectodomain of SIV gp41
EMBO Journal, 1998Michael Caffrey +2 more
exaly
Activation of Human Microglial Cells by HIV-1 gp41 and Tat Proteins
Clinical Immunology, 2000Stanley Thayer, P K Peterson, W S Sheng
exaly
HIV-1 resistance to the gp41-dependent fusion inhibitor C-34
Antiviral Research, 2003Arantxa Gutierrez, JOSÉ Este
exaly
Characterization of a trimeric MPER containing HIV-1 gp41 antigen
Virology, 2009Michael Seaman +2 more
exaly

